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AbstrAct
Objective The aim of this systematic review and meta-
analysis of randomised controlled trials (RCTs) and 
observational studies is to assess the effect of decision 
aids (DAs) in women aged 50 and below facing the 
decision to be screened for breast cancer.
setting Screening for breast cancer.
Intervention DAs aimed to help women make 
a deliberative choice regarding participation in 
mammography screening by providing information on the 
options and outcomes.
Eligible studies We included published original, non-pilot, 
studies that assess the effect of DAs for breast cancer 
screening. We excluded the studies that evaluated only 
participation intention or actual uptake. The studies’ risk 
of bias was assessed with the Cochrane Collaboration’s 
tool for RCTs and the National Institutes of Health Quality 
Assessment Tool for non-RCTs.
Primary and secondary outcomes The main outcome 
measures were informed choice, decisional conflict and/
or confidence, and knowledge. Secondary outcomes were 
values, attitudes, uncertainty and intention to be screened.
results A total of 607 studies were identified, but only 
3 RCTs and 1 before-after study were selected. The use 
of DAs increased the proportion of women making an 
informed decision by 14%, 95% CI (2% to 27%) and the 
proportion of women with adequate knowledge by 12%, 
95% CI (7% to 16%). We observed heterogeneity among 
the studies in confidence in the decision. The meta-
analysis of the RCTs showed a significant decrease in 
confidence in the decision and in intention to be screened.
conclusions Tools to aid decision making in screening 
for breast cancer improve knowledge and promote 
informed decision; however, we found divergent results on 
decisional conflict and confidence in the decision. Under 
the current paradigm change, which favours informed 
choice rather than maximising uptake, more research is 
necessary for the improvement of DAs.
IntrOductIOn
In Western countries, screening for breast 
cancer (BC) spread during the 1990s. There 
was a general consensus on the benefits 
of screening since several clinical trials in 
the USA and Northern Europe estimated a 
statistically significant and clinically relevant 
reduction in mortality from BC.1 But in the 
year 2000 the systematic review from Gotzsche 
and Olsen  started a hot debate, still alive, on 
the relevance and magnitude of benefits and 
harms of BC screening.2
More than two decades after the introduc-
tion of BC mass screening, the evidence on 
the harm-benefit balance remains inconclu-
sive. On the one hand, advances in adjuvant 
treatments, a multidisciplinary approach 
for BC treatment and earlier identification 
of symptoms by women have diminished the 
impact of screening on BC mortality reduc-
tion.3–5 On the other hand, the evidence on 
adverse effects of screening, characterised 
by a high consensus on the risk of false-pos-
itive results and lack of agreement on the 
size of overdiagnosis and overtreatment, 
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Research
strengths and limitations of this study
 ► This is the first systematic review focused in the 
impact of decision aids (DA) about breast cancer 
screening on informed choice, decisional conflict, 
knowledge, values, attitudes and intention to be 
screened.
 ► The review focused on studies that assess DAs 
designed to inform and help women to decide, not 
on those aimed at encouraging participation and 
adherence.
 ► A limitation of the review is the reduced number 
of studies included, which can be explained by 
the recent development of DAs for breast cancer 
screening.
 ► There was variability in the type and amount of 
information included in the DAs and also in the 
information given to the control group; this variability 
may explain part of the significant heterogeneity in 
all the outcomes evaluated.
 ► The DAs were designed in Australia, the USA and 
Germany, and women included had higher education 
levels than women in the general population, limiting 
the generalisability of the results.
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shows that the potential harms of screening are not 
insignificant.6–8
The current prevailing paradigm, which encourages 
participation, is changing. Two proposals are gaining 
strength. First, the need to inform women of potential 
benefits and harms of screening. Some propose not 
devoting more energy to increasing participation, but 
dedicating it to informing women to help them make the 
best decision based on their preferences and values.9–12 
Second, customising the screening strategies to indi-
vidual risk. Some recent studies13–15 based on mathe-
matical models suggest that risk-based screening may 
increase benefits and reduce harms. The literature shows 
that both proposals are gaining strength.16 17
Decision aids (DAs) are instruments that communicate 
evidence-based information on the benefits and harms 
of different healthcare options to help people make 
informed choices. The Stacey et al work,18 a recently 
updated Cochrane systematic review on DAs for people 
facing treatment or screening decisions, included 105 
published randomised controlled trials (RCTs) of DAs, 
26 of which dealt with cancer screening (13 prostate, 10 
colon, 2 breast and 1 cervix) and 4 on BC genetic testing. 
The authors concluded that, compared with usual 
care, DAs increase participants’ knowledge, objectively 
measured. In addition, people exposed to DAs feel more 
knowledgeable, better informed and clearer about their 
values, and they probably have a more active role in deci-
sion making and more accurate risk perceptions. In addi-
tion, Stacey et al18 think that more research is needed on 
their effects on adherence to the chosen option, cost-ef-
fectiveness and use with lower literacy populations.
Information on cancer screening is often biased, 
incomplete and persuasive.19 Some leaflets mention the 
possibility of harms, however they do not quantify them. 
In Europe, some organisations are providing information 
on benefits and harms of BC screening, in particular, 
estimates of mortality reduction, and the frequency of 
false-positive results of mammography and invasive tests 
(eg, Cochrane Collaboration, UK NHS Breast Screening 
Programme; German Institute for Quality and Efficiency 
in Health Care; Fundació Lliga per a la Investigació i 
Prevenció del Càncer and Agència de Salut Pública de 
Barcelona, in Catalonia (Spain)). Information on overdi-
agnosis appears in some of the information materials. Two 
recent studies11 20 have compared the impact of adding 
information on overdiagnosis to support informed choice 
on BC screening. In preparation for a RCT on the effect 
of a DA in mass screening in two regions of Spain, we 
aimed to identify and summarise all the studies reporting 
the description and assessment of a DA when applied 
to women aged 50 and below facing the decision to be 
screened with mammography in a population-based 
screening or opportunistic case-finding framework. We 
expected to find that DAs improve knowledge of options, 
benefits and harms; create accurate perceptions of bene-





We included all the published studies with RCT or before-
after designs that compared a DA to no intervention, usual 
care or alternative interventions. The search date upper 
limit was 31 December 2016. Pilot studies were excluded.
Types of participants
Participants were women facing decisions about screening 
in a population-based screening or opportunistic case-
finding framework within the age interval of recom-
mended mammography screening. We excluded studies 
aimed at elderly women only, and studies where partici-
pants were asked to make hypothetical choices.
Types of interventions
DAs were defined as interventions aimed to help women 
make a deliberative choice regarding participation in 
mammography screening, by providing information on 
the options and outcomes. We excluded studies aimed at 
increasing participation or promoting adherence, and 
studies not carried out in the context of women facing a 
real decision.
Types of outcome measures
The primary outcomes were: informed choice based on 
values, decisional conflict and/or confidence, and knowl-
edge. The secondary outcomes included: values and/or 
attitudes towards screening, proportion remaining unde-
cided and proportion reporting intention to be screened.
Language
We included articles reported in any language.
Information sources
Search methods for identification of studies
The search strategy was performed in MEDLINE and 
SCOPUS and adapted and replicated in EMBASE, 
CINAHL, PsycINFO and the Cochrane Library Plus. 
The search included the keywords ‘breast cancer’ and 
‘decision’ (or ‘choice’) and ‘aid’ (or ‘informed’) and 
‘mammography’ (or ‘mammogram’), within the paper 
title or the abstract. It excluded the keyword ‘protocol’ 
from the paper titles and allowed synonyms and free 
suffixes and prefixes. The reviews identified by this 
search, as well as the references that they included, were 
exhaustively used to refine the search strategy to ensure 
that all the possible relevant references for our review 
were identified (see online supplementary appendix 1).
study selection and synthesis of results
All the studies satisfying the inclusion criteria regarding 
design, participants and interventions were included in 
this review. Selection and the assessment of risk of bias 
was independently conducted in pairs by four reviewers 
(MCL, MJPL, MMA and MR). In the case of disagreement, 
studies were discussed by the whole team of reviewers 
until an agreement was reached.
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Data extraction
The data extraction for the selected studies was inde-
pendently conducted by two reviewers (MMA and MR) 
and a consensus version was obtained. In the case that 
the necessary data were not provided in the articles, the 
corresponding authors were contacted.
Risk of bias of individual studies
For the risk of bias assessment, we used the Cochrane risk 
of bias tool for RCTs and the National Institutes of Health 
quality assessment tool for non-RCTs.21 In case of non-RCTs, 
the selection, allocation and blinding assessments were 
not applicable. Sampling bias (a problem for external 
validity) was assessed in all the included studies.
The risk of bias (low, unclear or high) was assessed consid-
ering the study design and the methodological quality of the 
studies. Data consistency was rated as no inconsistency, incon-
sistency present or not applicable if there was only one study 
available, considering each outcome’s direction, magnitude 
and statistical significance over the set of included studies. 
The assessment methods followed the AHRQ ‘Methods 
Guide for Effectiveness and Comparative Effectiveness 
Reviews’ (www. effectivehealthcare. ahrq. gov/) and were in 
accordance with the PRISMA (Preferred Reporting Items 
for Systematic Reviews and Meta-analyses) checklist.22
Analysis of results
For each endpoint of interest, the decision to combine the 
results of the selected studies in a meta-analysis was based 
on the heterogeneity of patient populations and interven-
tions, as well as on the methodological heterogeneity of 
study designs and reported outcomes. Consistency and 
heterogeneity of the studies’ results were assessed with 
the I2 index and the Q test, respectively.
If comparable measures were obtained, we pooled the 
data for the outcomes. To facilitate the data pooling, scores 
with different ranges (minimum and/or maximum values) 
were standardised to range from 0 to 100 points. We esti-
mated a weighted effect intervention (with 95% CI) as the 
difference between the intervention and control groups 
in experimental designs, and as changes from baseline 
assessed in outcome measures postintervention in before-
after studies. Mean differences or pooled relative risks 
were estimated for continuous or dichotomous outcomes, 
respectively. The summary effects of the intervention were 
obtained using random effects meta-analysis. An additional 
meta-analysis of the RCTs was performed. We used the 
library metafor of the R package.23
rEsults
study selection
In total, we identified 607 unique citations from the elec-
tronic database searches. Of these, only 14 were selected 
for evaluation of the inclusion and exclusion criteria. 
Figure 1 presents the flow chart of the study selection 
process. Ten studies were excluded after full text assess-
ment (see table A2.1 in online supplementary appendix 2 
for details). Finally, three randomised controlled studies 
(Mathieu et al,24 Gummersbach et al20 and Hersch et al11) 
and one before-after study (Eden et al25) were selected. 
These four studies involved a total of 1650 participants 
from four countries (two from Australia, one each from 
Germany and the USA).
study characteristics
Table 1 presents the studies' characteristics. Gummers-
bach and Hersch compared two DAs with information 
about the benefits and harms of mammography screening, 
providing the intervention group with more complete 
information. Whereas Gummersbach added more critical 
information on the harms of screening mammography in 
the intervention group, the DA in Hersch only differed in 
providing thorough information of overdetection or not. 
In contrast, Mathieu compared a DA with receiving no 
information, and Eden assessed changes after providing 
a DA. It is important to notice that whereas Hersch and 
Gummersbach targeted women who were approaching 
50 and deciding whether to screen as per their national 
programme, Mathieu included younger women consid-
ering whether to start screening in their 40s, before the 
recommended age of 50 in Australia. Participants’ char-
acteristics are shown in table 2. Means of age were located 
in the 40–50 years interval. There are differences between 
studies in the prevalence of previous mammograms and 
in education level.
risk of bias in the included studies
The evaluation of the risk of bias for the RCTs included 
the assessment of bias in selection, performance, detec-
tion, attrition, reporting, sampling or any other source 
of bias. Details on the authors’ judgement and rationale 
for risk of bias can be found in tables A2.2–A2.5 (online 
supplementary appendix 2). The majority of assessed 
criteria were judged as low risk. Hersch et al11 was the only 
study free of a high risk of bias in all the domains assessed. 
Gummersbach et al20 was rated as having a high risk of 
attrition bias due to a high level of non-response. Mathieu 
et al24 was rated as having an unclear risk of allocation 
concealment and also of selective reporting. Eden et al25 
included a small sample of women with greater than a 
high school education, in a single rural geographical area. 
Therefore, the sample representativeness was limited.
Main outcomes
Tables 3 and 4 present the risk differences for the 
dichotomous outcomes and the mean differences for 
the continuous outcomes, respectively. Figures 2 and 
3 show the results of the meta-analyses for the dichot-
omous and continuous outcomes, respectively. The 
results of the meta-analysis performed exclusively on the 
RCTs are presented in table A3.1, online supplementary 
appendix 3.
Informed choice
The DAs increased the proportion of women making an 
informed decision, 58.0% vs 36.5% according to Mathieu 
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Figure 1 Study flow diagram.
(p<0.001) and 24.2% vs 15.4% according to Hersch 
(p=0.002). The meta-analysis estimation of risk difference 
was 14%, 95% CI (2% to 27%) (table 3 and figure 2).
Decisional conflict and/or decisional confidence
Eden observed a significant postintervention decrease in 
decisional conflict and a significant increase in decisional 
confidence (table 4, figure 3). In contrast, Hersch noted 
no significant effect of the intervention on decisional 
conflict and a significant decrease in decisional confi-
dence, observed also by Gummersbach. These contradic-
tory results introduced high heterogeneity that increased 
the uncertainty about the overall impact of a DA on 
decisional conflict and/or confidence (figure 3). The 
meta-analysis of the RCTs showed a significant decrease 
in the confidence scale (table A3.1, online supplemen-
tary appendix 3).
Knowledge
The use of a DA increased knowledge according to all 
studies, although the positive difference was not statisti-
cally significant in the Gummersbach study (tables 3 and 
4). The overall results provided by the meta-analyses were 
statistically significant, either in the proportion of women 
with adequate knowledge, with a significant increase of 
12%, 95% CI (7% to 16%), or in the mean score, with a 
difference of 0.70 out of 10 points, 95% CI (0.27 to 1.13) 
(figures 2 and 3).
secondary outcomes
The high heterogeneity of the results did not make it 
possible to reach conclusions about significant postinter-
vention changes or differences in secondary outcomes, 
such as positive attitudes and values towards screening, 
decisions about screening and intention to be screened 
(table 3, figure 2). The results of the meta-analysis 
performed exclusively on the RCTs are presented in table 
A3.2, online supplementary appendix 3.
Positive attitudes/values towards screening
Mathieu did not show any significant difference in atti-
tudes, but Hersch obtained a significantly lower frequency 
of women with positive attitudes towards screening among 
women receiving the DA with overdiagnosis information.
Undecided about BC screening
Mathieu reported a significant decrease in the frequency 
of women undecided about BC screening after the DA 
administration. In contrast, Hersch obtained a signifi-
cant increase for the intervention group, with the DA 
including thorough overdiagnosis information.
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Table 1 Description of the studies’ characteristics
Study Design Age group Exclusion criteria Decision aid (DA)




38–45 Personal history of breast cancer 
(BC)
Web-based DA, information on possible 
screening outcomes and worksheet to 
help weigh up and clarify preferences. 
Intervention group: immediate access; 
control group: delayed access after 
completing the outcome measures.
Eden et al25 Before-after 
study, clinical
40–49 Personal history of BC, prior 
breast biopsy, high risk of BC†, 
previous mammography within 
1 year, non-English speaking
Web-based DA in three rural clinical settings, 
including BC information and questions for 







48–49 None Mailed leaflet, more informative (especially 
on overdiagnosis) for the intervention group. 
The leaflet was not created in accordance 
with published criteria for evidence-based 
patient information, but it contained much 
more information relevant to decision making 
than the leaflet of the control group.





48–50 Personal or strong family 
history of BC, BC risk higher 
than average, mammography 
in the past 2 years, non-English 
speaking
Mailed DA, outcomes assessed by phone 
interview. Evidence-based explanatory and 
quantitative information on overdiagnosis, 
BC mortality reduction, and false positives 
for the intervention group versus information 
on BC mortality reduction and false positives 
for the control group.
*The trial was advertised on the media. Women had free access to the site for eligibility assessment.
†Breast cancer risk based on the B-RST (Breast Cancer Genetics Referral Screening Tool).
Table 2 Description of studies’ participants
Study Group Participants Age mean (SD) Previous mammography University degree
Mathieu et al24 Intervention 172 41.9 (2.0)* 53 (30.8%) 76 (44.2%)†
Control 212 41.8 (2.2)* 52 (24.5%) 126 (59.4%)†
Eden et al25 Before-after 75 45.0 (2.5) 51 (68.0%) 34 (45.3%)
Gummersbach et al20 Intervention 178 48.67 (0.79) ‡ 33 (18.5%)
Control 175 48.76 (0.80) ‡ 23 (13.2%)
Hersch et al11 Intervention 419 49.67 (0.44) § 119 (28.4%)
Control 419 49.70 (0.44) § 123 (29.4%)
*Out of the assessed participants, 116 and 198 in intervention and control groups, respectively.
†Out of the assessed participants, 114 and 199 in intervention and control groups, respectively.
‡Three and four women with breast cancer in intervention and control groups, respectively. Participants were not asked about 
mammographic exams in the past.
§No women with previous mammogram in the previous 2 years but it is not stated how many women had mammograms more than 2 years 
before being included in the study.
Intention to be screened
Hersch noted a statistically significant decrease in the 
intention to be screened and Gummersbach a nearly 
significant decrease. The meta-analysis of the RCTs 
showed a significant decrease in the intention to be 
screened, 7%, 95% CI (2% to 15%) (table A3.2, online 
supplementary appendix 3). The lower proportions 
intending to screen in the Mathieu study with respect to 
the other studies (table 3) can be attributed to the fact 
that women were younger than 50, the recommended age 
for starting screening in Australia.
dIscussIOn
summary of main results
This systematic review includes three RCTs and one 
before-after study assessing DAs given to women facing 
the decision to be screened with mammography. There 
was variability in the type and amount of information 
included in the DAs, and also in the information given 
to the control group. This variability may explain, in 
part, the significant heterogeneity in all the outcomes 
evaluated. Despite this heterogeneity, the meta-anal-
ysis revealed that DAs produce a statistically significant 
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Table 3 Risk differences for the dichotomous outcomes: informed choice, knowledge, positive attitudes/values towards 
screening, undecided and intention to be screened
Outcome Study Group Assessed n (%) Difference, p value*
Informed choice† Mathieu et al24‡ Intervention 112 65 (58.0%) 21.5%, p<0.001
Control 192 70 (36.5%)
Hersch et al11§ Intervention 409 99 (24.2%) 8.8%, p=0.0017
Control 408 63 (15.4%)
Knowledge Mathieu et al24¶ Intervention 113 106 (93.8%) 10.7%, p=0.01
Control 189 157 (83.1%)
Hersch et al11** Intervention 419 122 (29.1%) 13.0%, p<0.001
Control 419 71 (16.9%)
Positive attitudes†† Mathieu et al24 Intervention 111 88 (79.3%) 0.2%, p=0.89
Control 182 144 (79.1%)
Hersch et al11 Intervention 409 282 (68.9%) −14.4%, p<0.001
Control 408 340 (83.3%)
Undecided Mathieu et al24 Intervention 117 21 (17.9%) −21.3%, p<0.001
Control 209 82 (39.2%)
Hersch et al11 Intervention 419 69 (16.5%) 9.3%, p<0.001
Control 419 30 (7.2%)
Intention to be screened Mathieu et al24 Intervention 117 50 (42.7%) 3.0%, p=0.64
Control 209 83 (39.7%)
Eden et al25 Before 75 54 (72.0%) 6.7%‡‡, p=0.123
After 75 59 (78.7%)‡‡
Gummersbach et al20 Intervention 178 145 (81.5%) −7.1%, p=0.06
Control 175 155 (88.6%)
Hersch et al11 Intervention 419 308 (73.5%) −13.1%, p<0.001
Control 419 363 (86.6%)
*Fisher’s exact test.
†Eden provided only a postintervention mean of the preparation for decision-making scale of 73.2 (18.1).
‡Out of the women assessed, including undecided women in the denominator.
§Informed choice defined as adequate knowledge and intentions consistent with attitudes.
¶Knowledge (according to Mathieu): score higher than 5 out of 10.
**Knowledge (according to Hersch): adequate knowledge when scoring at least 50% of the total available marks, including at least one 
numerical mark, on all three screening outcome subscales (breast cancer mortality benefit, false-positive screening result and overdiagnosis).
††Positive attitudes/values >50 out of 100 according to Mathieu and ≥24 out of 30 according to Hersch.
‡‡Difference as postintervention minus preintervention values.
improvement in knowledge of screening outcomes as 
well as a significant increase in the frequency of women 
making an informed choice. However, no significant 
effects were observed for decision conflict, decision 
confidence and positive attitudes towards screening. 
Therefore, the overall conclusion from our review is 
that DAs significantly increase women's knowledge 
and therefore the proportion of women making an 
informed choice, but do not significantly modify atti-
tudes or intentions towards screening. It is important to 
mention that when the meta-analysis was performed on 
the RCT subgroup, we found a significant decrease in 
confidence in the decision and intention to be screened. 
This decrease in screening intention is consistent with 
the findings of Ivlev et al26 in a recently published system-
atic review of the effect of DAs on women's intentions to 
undergo screening mammography in age groups where 
shared decision making is recommended.
Similarly, no significant effects were observed for the 
secondary outcomes that measured the frequency of 
participants remaining undecided or choosing to be 
screened. More specifically, Eden detected a signifi-
cant decrease in intraindividual postintervention deci-
sion conflict, which was not observed by Hersch, when 
comparing women receiving a DA with overdiagnosis 
information versus those without it. Indeed, Eden also 
obtained a significant improvement in intraindividual 
postintervention decision confidence, while Gummers-
bach and Hersch obtained a significant decrease in deci-
sion confidence when comparing women receiving a DA 
with exhaustive information on screening adverse effects 
versus those without it. This result can be explained 
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Table 4 Mean differences for the continuous outcomes: knowledge, decisional conflict and decisional confidence
Outcome Study Group N Mean (SD) Difference, p value
Knowledge Mathieu et al24* Intervention 113 7.35 (1.84) 1.1, p<0.001
Control 189 6.27 (1.85)
Gummersbach et al20* Intervention 161 5.49 (1.99) 0.26, p=0.26
Control 168 5.23 (2.06)
Hersch et al11† Intervention 419 13.49 (4.36) 1.65, p<0.001
Control 419 11.84 (3.74)
Decisional conflict Eden et al25‡ Before 75 46.33 (27.04) −38.0, p<0.001
After 75 8.33 (15.58)
Hersch et al11 Intervention 419 12.55 (17.60) 0.35, p=0.78
Control 419 12.20 (18.90)
Decisional confidence Eden et al25§ Before 75 79.67 (18.62) 16.16, p<0.001
After 75 95.73 (6.86)
Gummersbach et al20¶ Intervention 178 5.15 (1.36) −0.37, p=0.017
Control 182 5.52 (0.93)
Hersch et al11** Intervention 419 4.35 (0.74) −0.18, p=0.0003
Control 419 4.53 (0.67)
*Knowledge scored, range 0–10.
†Knowledge scored, range 0–22.
‡Decision conflict scale, range 0–100.
§Self-efficacy scale, range 0–100.
¶Confidence scale, range 0–6.
**Confidence scale, range 0–5 (mean of 3 subscales).
by the impact of the information on adverse events of 
screening. Positive attitudes towards screening signifi-
cantly decreased when overdiagnosis information was 
added to the DA, as observed by Hersch, in contrast 
with the absence of change observed by Mathieu. The 
frequency of women remaining undecided after DAs 
showed completely contradictory results. While Mathieu 
observed a very significant decrease, Hersch obtained a 
significant increase. The frequency of women decided 
to be screened showed a significant difference in the 
Hersch study, where a decrease was observed for the 
group provided with overdiagnosis information, while 
Gummersbach, the other study incorporating thorough 
information on mammography adverse effects, showed a 
nearly significant decrease.
Quality of the evidence
Risk of bias ratings shows that the included studies had 
a low risk of bias in most of the assessed domains. There 
may have been publication bias due to failure to report 
negative findings. Several of the outcomes showed a high 
level of heterogeneity that limits the interpretation of the 
pooled effect size.
strengths and limitations
This is the first systematic review focused on the impact of 
DAs about BC screening on informed choice and other 
relevant outcomes from the women's perspective. Our 
review focused on studies that assess DAs designed to 
inform and help women to decide, not on studies aimed 
at encouraging participation and adherence.
Studies differed in design, especially in terms of the 
control group. In the Mathieu et al study,24 the control 
group did not receive the DA until the outcome measures 
had been completed. The Eden et al study25 assessed the 
postintervention intraindividual changes after the DA was 
provided. In the Gummersbach et al study,27 a more infor-
mative leaflet was compared with a less informative one. 
Finally, in the Hersch et al study,11 the intervention DA 
had evidence-based explanatory and quantitative infor-
mation on overdiagnosis, BC mortality reduction and 
false positives, whereas the control DA included infor-
mation on BC mortality reduction and false positives. 
Previous knowledge was not measured in the Mathieu 
and Gummersbach RCTs, although one expects that 
both groups had similar knowledge about mammography 
screening at baseline. Hersch et al11 measured some basic 
knowledge at baseline using a subset of items and showed 
similar results between groups. In the Eden study, which 
assessed intraindividual changes, the DA was particularly 
useful for the least informed and least confident women. 
On the other hand, Gummersbach et al20 noted that 
education level was positively associated with acquired 
knowledge and that the less educated women had less 
relevant decisional knowledge after reading the leaflet, 
but they were more willing to undergo mammography 
than more educated women. Only the Hersch study 
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Figure 2 Meta-analysis of risk differences for the dichotomous outcomes (random effects (RE) model). Heterogeneity 
measures: informed choice: I2=74.7%, Q test p=0.047; knowledge: I2=0%, Q test p=0.75; positive attitudes: I2=84.6%, Q test 
p=0.011; undecided: I2=96.9%, Q test p<0.001; intention to be screened: I2=75.9%, Q test p=0.008.
included a follow-up for final screening participation, but 
the results are not published yet.
The limitations of the study are principally related with 
the generalisation of the results. Women included in the 
studies probably had a higher education level, greater 
health awareness and were more actively involved in 
healthcare decisions than women in the general popu-
lation. In addition, the DAs were designed using specific 
data from Australia (Mathieu and Hersch), the USA 
(Eden) and Germany (Gummersbach), providing results 
which may not be generalisable to other countries. All 
studies evaluated the DAs only from the women’s perspec-
tive, and in the context of research, where participants 
may have a higher level of commitment than women 
invited to participate in a breast screening programme.
unanswered questions and future research
Women should use DAs to be informed and support their 
decisions about BC screening given their preferences 
and attitudes. It is important to ensure that the informa-
tion provided is well understood by all women, including 
those with lower level of education.
The internet is an inexpensive tool for the dissem-
ination of DAs or to provide additional information, if 
necessary, in order to present women with all the options 
available and the harms and benefits of each of them. But 
there are women who are not familiarised with or do not 
have access to the internet and therefore other ways to 
disseminate information are also needed.
According to Gummersbach, the doctor’s advice was 
the most important factor helping with the decision to be 
screened for almost half of the women. This result indi-
cates the importance of shared decision making, where 
DAs are essential tools. Shared decision making can also 
help reduce decisional conflict and improve confidence 
when information on screening harms is provided. In our 
search, we found 17 papers that described interventions 
to increase uptake compared with 4 studies designed 
to increase knowledge about the benefits and harms of 
the intervention. Given that the search was not designed 
to identify studies with ‘increased uptake’, this finding 
adds information to the important debate about medical 
ethics in relation to screening interventions—basically 
the old-fashioned paternalistic attitude versus citizen 
involvement and shared decision making.
As highlighted by Hersch et al, establishing what consti-
tutes an informed choice, and what knowledge is needed 
in order to be informed, is an important issue and no 
consensus currently exists on what knowledge constitutes 
being objectively informed enough for an informed or 
shared decision. When Hersch et al used an expert-led 
approach based on medical guidelines and under-
pinned by decision theory, which required numerical 
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Figure 3 Meta-analysis of mean differences in scores for the quantitative outcomes (random effects (RE) model). 
Heterogeneity measures: decision conflict: I2=99.0%, Q test p<0.001; decision confidence: I2=98.3%, Q test p<0.001; 
knowledge: I2=75.7%, Q test p=0.030.
and conceptual knowledge, only 24% in the interven-
tion group and 15% in the control group were assessed 
as informed. When only conceptual knowledge was 
required, these proportions increased to 50% and 19%, 
respectively. Difficulties understanding quantitative infor-
mation or the widespread positive value placed on cancer 
screening can produce a certain resistance to information 
on possible harms. Their study was the only one obtaining 
a significant increase in the amount of women remaining 
undecided about being screened in the group receiving 
information on overdiagnosis.
The DAs of the included studies lacked detailed infor-
mation on the outcomes of screening, detection, treat-
ment, or financial strain and opportunity costs from the 
perspective of the society, which could be considered 
important for inclusion in future DAs.
cOnclusIOns
DAs for BC screening can improve knowledge and 
promote informed decision making, in accordance with 
their preferences, for women who face the decision of 
screening. However, we found divergent results on deci-
sional conflict and decision confidence. Under the new 
paradigm, which favours informed choice rather than 
maximising uptake, more research is necessary for the 
improvement of DA.
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